Hepatic Mitochondrial Alteration in CD-1 Mice Associated with Prenatal Exposures to Low Doses of Perfluorooctanoic Acid (PFOA)

Toxicologic Pathology

Volumn 43, Issue 4, 2015, Pages 546-557

  Quist, Erin M ^a,b   Filgo, Adam J ^a,c   Cummings, Connie A ^d   Kissling, Grace E ^a   Hoenerhoff, Mark J ^a   Fenton, Suzanne E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UltraPath Imaging   (United States)

Author keywords

hepatocellular hypertrophy; liver; mitochondrial damage; mouse; peroxisome proliferation; PFOA; PPAR

Indexed keywords

PERFLUOROOCTANOIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; FEEDING; FEMALE; GESTATIONAL AGE; HISTOPATHOLOGY; INFLAMMATION; LIVER CELL; LIVER HYPERTROPHY; LIVER MITOCHONDRION; MOUSE; NONHUMAN; PERINATAL PERIOD; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; LIVER; METABOLISM; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; BODY WEIGHT; CAPRYLATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROCARBONS; HEPATOCYTES; LIVER; MICE; MITOCHONDRIA, LIVER; PPAR ALPHA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84930345579     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623314551841     Document Type: Article

References (20)

1. Abbott B. D. Wood C. R. Watkins A. M. Tatum-Gibbs K. Das K. P. Lau C. (2012). Effects of perfluorooctanoic acid (PFOA) on expression of peroxisome proliferator-activated receptors (PPAR) and nuclear receptor-regulated genes in fetal and postnatal CD-1 mouse tissues. Reprod Toxicol 33, 491–505.
2. Berthiaume J. Wallace K. B. (2002). Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicology Letters 129, 23–32.
3. CDC (Centers for Disease Control). (2013). Fourth National report on human exposure to environmental chemicals. Accessed May 12, 2014, http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Sep2013.pdf.
4. Cheville N. F. (2013). Ultrastructural pathology and interorganelle cross talk in hepatotoxicity. Toxicol Pathol 41, 210–26.
5. Emmett E. A. Shofer F. S. Zhang H. Freeman D. Desai C. Shaw L. M. (2006). Community exposure to perfluoroocatnoate: Relationships between serum concentrations and exposure sources. J Occup Environ Med 48, 759–70.
6. Filgo A. J. Quist E. M. Hoenerhoff M. J. Brix A. E. Kissling G. E. Fenton S. E. (2014). Perfluorooctanoic acid (PFOA)-induced liver lesions in two strains of mice following developmental exposures: PPARα is not required. Manuscript submitted for publication in Toxicological Pathology.
7. Gallo V. Leondardi G. Genser B. Lopez-Espinosa M. Frisbee S. J. Karlsson L. Ducatman A. M. Fletcher T. (2012). Serum perfluorooctanoate (PFAO) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect 120, 655–60.
8. Hall A. P. Elcombe C. R. Foster J. R. Harada T. Kaufmann W. Knippel A. Küttler K. Malarkey D. E. Maronpot R. R. Nishikawa A. Nolte T. Schulte A. Strauss V. York M. J. (2012). Liver hypertrophy: A review of adaptive (Adverse and nonadverse) changes—Conclusions from the 3rd International ESTP expert workshop. Toxicol Pathol 40, 971–94.
9. Hines E. P. White S. S. Stanko J. P. Gibbs-Flournoy E. A. Lau C. Fenton S. E. (2009). Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. Mol Cell Endocrinol 304, 97–105.
10. Huang Q. Zhang J. Martin F. L. Peng S. Tian M. Mu X. Shen H. (2013). Perfluorooctanoic acid induces apoptosis through the p53-dependent mitochondrial pathway in human hepatic cells: A proteomic study. Toxicol Lett 223, 211–20.
11. Lau C. (2012). Perfluorinated Compounds. In Molecular, Clinical and Environmental Toxicology, Experientia Supplementum (Luch A., ed.), Vol. 101, pp. 47–86. Springer, Basel.
12. Lau C. Thibodeaux J. R. Hanson R. G. Narotsky M. G. Rogers J. M. Lindstrom A. B. Strynar M. J. (2006). Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci 90, 510–18.
13. Lindstrom A. B. Strynar M. J. Libelo E. L. (2011). Polyflorinated compounds: Past, present, and future. Environ Sci Technol 45, 7954–61.
14. Macon M. B. Villanueva L. R. Tatum-Gibbs K. Zehr R. D. Strynar M. J. Stanko J. P. White S. S. Helfant L. Fenton S. E. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: Low-dose developmental effects and internal dosimetry. Toxicol Sci 122, 134–45.
15. Post G. B. Cohn P. D. Cooper K. R. (2012). Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: A critical review of recent literature. Environ Res 116, 93–117.
16. Rosen M. B. Thibodeaux J. R. Wood C. R. Zehr R. D. Schmid J. E. Lau C. (2007). Gene expression profiling in the lung and liver of PFOA-exposed mouse fetuses. Toxicology 239, 15–33.
17. Stalker M. J. Hayes M. A. (2007). Liver and biliary system. In Jubb, Kennedy and Palmer’s Pathology of Domestic Animals (Maxie M. G., ed.), 5th ed., Vol. 2, pp. 306. Elsevier, Philadelphia, PA.
18. Starkov A. A. Wallace K. B. (2002). Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol Sci 66, 244–52.
19. Wolf D. C. Moore T. Abbott B. D. Rosen M. B. Das K. P. Zehr R. D. Lindstrom A. B. Strynar M. J. Lau C. (2008). Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPARα knockout and wild-type mice. Toxicol Pathol 36, 632–39.
20. Yang Q. Abedi-Valugerdi M. Xie Y. Zhao X. Möller G. Nelson B. D. DePierre J. W. (2002). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int Immunopharmacol 2, 389–97.